Last reviewed · How we verify
rFIX-R
rFIX-R is a recombinant coagulation factor IX used to treat bleeding episodes in patients with hemophilia B.
rFIX-R is a recombinant coagulation factor IX used to treat bleeding episodes in patients with hemophilia B. Used for Treatment of bleeding episodes in patients with hemophilia B, Prevention of bleeding in patients with hemophilia B undergoing surgery.
At a glance
| Generic name | rFIX-R |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | coagulation factor |
| Target | factor IX |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
rFIX-R works by replacing the missing or defective factor IX in patients with hemophilia B, allowing for proper blood clotting and stopping bleeding episodes. This is particularly useful for patients who have developed antibodies against previous factor IX treatments, making it difficult to find an effective replacement therapy.
Approved indications
- Treatment of bleeding episodes in patients with hemophilia B
- Prevention of bleeding in patients with hemophilia B undergoing surgery
Common side effects
- Injection site reaction
- Headache
- Nausea
- Fatigue
Key clinical trials
- Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
- Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B (PHASE3)
- Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |